Motesanib is primarily investigated for its potential in treating various types of cancer, particularly thyroid cancer, non-small cell lung cancer, and breast cancer. It works by inhibiting specific receptors involved in tumor growth and blood vessel formation, which can help slow down or stop the progression of cancer. Additionally, it is studied for its role in combination therapies, where it may enhance the effectiveness of other anticancer drugs. Researchers are also exploring its use in managing other conditions where abnormal blood vessel growth plays a significant role, such as certain eye diseases. Clinical trials continue to evaluate its safety, efficacy, and optimal dosing in different patient populations.